Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

An update from Trinity Biotech ( ($TRIB) ) is now available. On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 News provided by Trinity Biotech plc Jan 28, 2025, 7:20 AM ET ...

-Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management -Upfront payment of $12.5 ...

David Ouston, Biosensor Marketing Director of Trinity Biotech, said, “We’ve made significant progress in the development of our next generation CGM, with an innovative reimagining of our ...

Trinity Biotech (TRIB) stock gains on encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose monitoring ( (CGM)) system. Read more here.

Trinity Biotech (TRIB) announced clinical trial results demonstrating a major technical breakthrough and de-risking the commercial pathway for its ...

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology Provided by GlobeNewswire Jan 28, 2025 4:20am ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management ...